- Home
- DXLG vs DTIL Comparison
DXLG vs DTIL Comparison
Compare DXLG & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | DTIL |
|---|---|---|
| Founded | 1976 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 123.0M |
| IPO Year | 1987 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DXLG | DTIL |
|---|---|---|
| Price | $1.17 | $4.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $47.00 |
| AVG Volume (30 Days) | 179.2K | ★ 197.0K |
| Earning Date | 12-11-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $447,744,000.00 | $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.95 | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.88 | $3.61 |
| 52 Week High | $3.10 | $8.82 |
Technical Indicators
Market Signals| Indicator | DXLG | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 42.57 |
| Support Level | $1.01 | $4.61 |
| Resistance Level | $1.58 | $5.20 |
| Average True Range (ATR) | 0.15 | 0.34 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 43.07 | 40.00 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.